Prevalence of prostate cancer metastases after intravenous inoculation provides clues into the molecular basis of dormancy in the bone marrow microenvironment

Neoplasia (United States)

Volumn 14, Issue 5, 2012, Pages 429-439

  Jung, Younghun ^a   Shiozawa, Yusuke ^a   Wang, Jingcheng ^a   Mcgregor, Natalie ^b   Dai, Jinlu ^b   Park, Serk In ^a   Berry, Janice E ^a   Havens, Aaron M ^a   Joseph, Jeena ^a   Kim, Jin Koo ^a   Patel, Lalit ^b   Carmeliet, Peter ^c   Daignault, Stephanie ^d   Keller, Evan T ^b   Mccauley, Laurie K ^a,b   Pienta, Kenneth J ^b   Taichman, Russell S ^a  

^a UNIVERSITY OF MICHIGAN SCHOOL OF DENTISTRY   (United States)

^b UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^c UNIVERSITY OF LEUVEN   (Belgium)

^d UNIVERSITY OF MICHIGAN COMPREHENSIVE CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GROWTH ARREST SPECIFIC PROTEIN 6; INTERLEUKIN 15; KI 67 ANTIGEN; LIPOCORTIN 2; MESSENGER RNA; MONOCYTE CHEMOTACTIC PROTEIN 1; STROMAL CELL DERIVED FACTOR 1; TRANSFORMING GROWTH FACTOR BETA1;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; BIOLUMINESCENCE; BONE LESION; BONE METASTASIS; CONTROLLED STUDY; DISSEMINATED CANCER; ENZYME LINKED IMMUNOSORBENT ASSAY; FLOW CYTOMETRY; FORELIMB; GENE EXPRESSION; HEMATOPOIETIC STEM CELL; HINDLIMB; HISTOLOGY; HUMAN; HUMAN CELL; MALE; METASTASIS; MOUSE; NICK END LABELING; NONHUMAN; PREVALENCE; PRIORITY JOURNAL; PROSTATE CANCER; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TUMOR GROWTH; TUMOR MICROENVIRONMENT;

EID: 84861687309     PISSN: 15228002     EISSN: 14765586     Source Type: Journal    
DOI: 10.1596/neo.111740     Document Type: Article

References (50)

1. Walczak JR and Carducci MA (2007). Prostate cancer: a practical approach to current management of recurrent disease. Mayo Clin Proc 82, 243-249.
2. Taichman RS, Loberg RD, Mehra R, and Pienta KJ (2007). The evolvingbiology and treatment of prostate cancer. J Clin Invest 117, 2351-2361.
3. Park SI, Kim SJ, McCauley LK, and Gallick GE (2010). Pre-clinical mousemodels of human prostate cancer and their utility in drug discovery. Curr Protoc Pharmacol 51, 14.
4. Fidler IJ and Nicolson GL (1976). Organ selectivity for implantation sur- vival and growth of B16 melanoma variant tumor lines. J Natl Cancer Inst 57,1199-1202.
5. Taichman RS, Cooper C, Keller ET, Pienta KJ, Taichman N, and McCauley LK (2002). Use of the stromal cell-derived factor-1/CXCR4 pathway in pros-tate cancer metastasis to bone. Cancer Res 62, 1832-1837.
6. Weilbaecher KN, Guise TA, and McCauley LK (2011). Cancer to bone: a fatal attraction. Nat Rev Cancer 11, 411-425.
7. Li X, Loberg R, Liao J, Ying C, Snyder LA, Pienta KJ, and McCauley LK (2009). A destructive cascade mediated by CCL2 facilitates prostate cancergrowth in bone. Cancer Res 69, 1685-1692.
8. Thudi NK, Martin CK, Murahari S, Shu ST, Lanigan LG, Werbeck JL, Keller ET, McCauley LK, Pinzone JJ, and Rosol TJ (2011). Dickkopf-1 (DKK-1)stimulated prostate cancer growth and metastasis and inhibited bone formation in osteoblastic bone metastases. Prostate 71, 615-625.
9. Shiozawa Y, Pedersen EA, Havens AM, Jung Y, Mishra A, Joseph J, Kim JK, Patel LR, Ying C, Ziegler AM, et al. (2011). Human prostate cancer metastasestarget the hematopoietic stem cell niche to establish footholds in mouse bone marrow. J Clin Invest 121, 1298-1312.
10. Wang J, Wang J, Dai J, Jung Y, Wei CL, Wang Y, Havens AM, Hogg PJ, Keller ET, Pienta KJ, et al. (2007). A glycolytic mechanism regulating an angiogenicswitch in prostate cancer. Cancer Res 67, 149-159.
11. Angelillo-Scherrer A, de Frutos P, Aparicio C, Melis E, Savi P, Lupu F, Arnout J, Dewerchin M, Hoylaerts M, Herbert J, et al. (2001). Deficiency or inhibitionof Gas6 causes platelet dysfunction and protects mice against thrombosis. Nat Med 7, 215-221.
12. Havens AM, Pedersen EA, Shiozawa Y, Ying C, Jung Y, Sun Y, Neeley C, Wang J, Mehra R, Keller ET, et al. (2008). An in vivo mouse model for humanprostate cancer metastasis. Neoplasia 10, 371-380.
13. Lee RH, Hsu SC, Munoz J, Jung JS, Lee NR, Pochampally R, and Prockop DJ (2006). A subset of human rapidly self-renewing marrow stromal cells preferen-tially engraft in mice. Blood 107, 2153-2161.
14. Bhattacharya D, Czechowicz A, Ooi AG, Rossi DJ, Bryder D, and Weissman IL (2009). Niche recycling through division-independent egress of hematopoieticstem cells. J Exp Med 206, 2837-2850.
15. Kiel MJ, Yilmaz OH, Iwashita T, Yilmaz OH, Terhorst C, and Morrison SJ (2005). SLAM family receptors distinguish hematopoietic stem and progenitorcells and reveal endothelial niches for stem cells. Cell 121(7), 1109-1121.
16. Taichman RS and Emerson SG (1994). Human osteoblasts support hematopoi-esis through the production of granulocyte colony-stimulating factor. J Exp Med 179, 1677-1682.
17. Song J, Kiel MJ, Wang Z, Wang J, Taichman RS, Morrison SJ, and Krebsbach PH (2010). An in vivo model to study and manipulate the hematopoietic stemcell niche. Blood 115, 2592-2600.
18. Taichman RS (2005). Blood and bone: two tissues whose fates are intertwinedto create the hematopoietic stem cell niche. Blood 105(7), 2631-2639.
19. Zhu J, Garrett R, Jung Y, Zhang Y, Kim N, Wang J, Joe GJ, Hexner E, Choi Y, Taichman RS, et al. (2007). Osteoblasts support B-lymphocyte commitment and differentiation from hematopoietic stem cells. Blood 109, 3706-3712.
20. Wang J, Ying G, Wang J, Jung Y, Lu J, Zhu J, Pienta KJ, and Taichman RS (2010). Characterization of phosphoglycerate kinase-1 expression of stromal cells derived from tumor microenvironment in prostate cancer progression. Cancer Res 70, 471-480.
21. Wang J, Shiozawa Y, Wang J, Wang Y, Jung Y, Pienta KJ, Mehra R, Loberg R, and Taichman RS (2008). The role of CXCR7/RDC1 as a chemokine receptorfor CXCL12/SDF-1 in prostate cancer. J Biol Chem 283, 4283-4294.
22. Sun YX, Pedersen EA, Shiozawa Y, Havens AM, Jung Y, Wang J, Pienta KJ, andTaichman RS (2008). CD26/dipeptidyl peptidase IV regulates prostate cancer metastasis by degrading SDF-1/CXCL12. Clin Exp Metastasis 25(7), 765-776.
23. Sun YX, Fang M, Wang J, Cooper CR, Pienta KJ, and Taichman RS (2007).Expression and activation of αvβ3 integrins by SDF-1/CXC12 increases the aggressiveness of prostate cancer cells. Prostate 67, 61-73.
24. Sun YX, Schneider A, Jung Y, Wang J, Dai J, Wang J, Cook K, Osman NI, Koh-Paige AJ, Shim H, et al. (2005). Skeletal localization and neutralization ofthe SDF-1(CXCL12)/CXCR4 axis blocks prostate cancer metastasis and growth in osseous sites in vivo. J Bone Miner Res 20(2), 318-329.
25. Sun Y-X, Wang J, Shelburne CE, Lopatin DE, Chinnaiyan AM, Pienta KJ, Rubin MA, and Taichman RS (2003). The expression of CXCR4 andCXCL12 (SDF-1) in human prostate cancers (PCa) in vivo. J Cell Biochem 89, 462-473.
26. Shiozawa Y, Havens AM, Jung Y, Ziegler AM, Pedersen EA, Wang J, Wang J, Lu G, Roodman GD, Loberg RD, et al. (2008). Annexin II /annexin II receptoraxis regulates adhesion, migration, homing, and growth of prostate cancer. J Cell Biochem 105, 370-380.
27. Blum DL, Koyama T, M'Koma AE, Iturregui JM, Martinez-Ferrer M, Uwamariya C, Smith JA Jr, Clark PE, and Bhowmick NA (2008). Chemokinemarkers predict biochemical recurrence of prostate cancer following prostatectomy. Clin Cancer Res 14, 7790-7797.
28. Wu TG, Perdigao JR, Umhoefer TK, Cao J, Ansari DA, Albrecht TB, Knutson EP, Rose WA, Jorgensen AJ, Ryan LM, et al. (2009). Heterogeneous interleu-kin-15 inducibilities in murine B16 melanoma and RM-1 prostate carcinoma by interferon-alpha treatment. J Interferon Cytokine Res 29, 719-728.
29. Salm SN, Burger PE, Coetzee S, Goto K, Moscatelli D, and Wilson EL (2005).TGF-{beta} maintains dormancy of prostatic stem cells in the proximal region of ducts. J Cell Biol 170, 81-90.
30. Buijs JT, Henriquez NV, van Overveld PG, van der Horst G, ten Dijke P, and van der Pluijm G (2007). TGF-β and BMP7 interactions in tumour progression and bone metastasis. Clin Exp Metastasis 24, 609-617.
31. Shiozawa Y, Pedersen EA, Patel LR, Ziegler AM, Havens AM, Jung Y, Wang J, Zalucha S, Loberg RD, Pienta KJ, et al. (2010). GAS6/AXL axis regulatesprostate cancer invasion, proliferation, and survival in the bone marrow niche. Neoplasia 12, 116-127.
32. Dormady SP, Zhang XM, and Basch RS (2000). Hematopoietic progenitor cellsgrow on 3T3 fibroblast monolayers that overexpress growth arrest-specificgene-6 (GAS6). Proc Natl Acad Sci USA 97, 12260-12265.
33. Koh AJ, Demiralp B, Neiva KG, Hooten J, Nohutcu RM, Shim H, Datta NS, Taichman RS, and McCauley LK (2005). Cells of the osteoclast lineage as medi-ators of the anabolic actions of parathyroid hormone in bone. Endocrinology 146(11), 4584-4596.
34. Paget S (1889). The distribution of secondary growths in cancer of the breast. Lancet 1, 571-573.
35. Rana A, Chisholm GD, Khan M, Sekharjit SS, Merrick MV, and Elton RA (1993). Patterns of bone metastasis and their prognostic significance in patientswith carcinoma of the prostate. Br J Urol 72, 933-936.
36. Ulmert D, Kaboteh R, Fox JJ, Savage C, Evans MJ, Lilja H, Abrahamsson PA, Bjork T, Gerdtsson A, Bjartell A, et al. (2012). A novel automated platform forquantifying the extent of skeletal tumour involvement in prostate cancer patients using the bone scan index. Eur Urol. E-pub ahead of print 2012 Jan 27.
37. Dennis ER, Jia X, Mezheritskiy IS, Stephenson RD, Schoder H, Fox JJ, Heller G, Scher HI, Larson SM, and Morris MJ (2012). Bone scan index: a quantita- tive treatment response biomarker for castration-resistant metastatic prostate cancer. J Clin Oncol 30, 519-524.
38. 18F-FDG in patients with progressive, metastatic prostate cancer. J Nucl Med 45, 366-373.
39. Chambers AF, Groom AC, and MacDonald IC (2002). Dissemination andgrowth of cancer cells in metastatic sites. Nat Rev Cancer 2, 563-572.
40. Tothill P (1984). Bone blood flow measurement. J Biomed Eng 6, 251-256.
41. Mazo IB, Gutierrez-Ramos JC, Frenette PS, Hynes RO, Wagner DD, and von Andrian UH (1998). Hematopoietic progenitor cell rolling in bone marrowmicrovessels: parallel contributions by endothelial selectins and vascular cell adhesion molecule 1. J Exp Med 188, 465-474.
42. Lehr JE and Pienta KJ (1998). Preferential adhesion of prostate cancer cells to ahuman bone marrow endothelial cell line. J Natl Cancer Inst 90, 118-123.
43. Cooper CR, McLean L, Walsh M, Taylor J, Hayasaka S, Bhatia J, and Pienta KJ (2000). Preferential adhesion of prostate cancer cells to bone is mediated by binding to bone marrow endothelial cells as compared to extracellular matrix components in vitro. Clin Cancer Res 6, 4839-4847.
44. Cooper CR, McLean L, Mucci NR, Poncza P, and Pienta KJ (2000). Prostatecancer cell adhesion to quiescent endothelial cells is not mediated by β-1 integrinsubunit. Anticancer Res 20, 4159-4162.
45. Sainaghi PP, Castello L, Bergamasco L, Galletti M, Bellosta P, and Avanzi GC (2005). Gas6 induces proliferation in prostate carcinoma cell lines expressingthe Axl receptor. J Cell Physiol 204(1), 36-44.
46. Shain SA (2004). Exogenous fibroblast growth factors maintain viability, pro-mote proliferation, and suppress GADD45α and GAS6 transcript content ofprostate cancer cells genetically modified to lack endogenous FGF-2. Mol Cancer Res 2(11), 653-661.
47. van Ginkel PR, Gee RL, Shearer RL, Subramanian L, Walker TM, Albert DM, Meisner LF, Varnum BC, and Polans AS (2004). Expression of the receptortyrosine kinase Axl promotes ocular melanoma cell survival. Cancer Res 64, 128-134.
48. Wu YM, Robinson DR, and Kung HJ (2004). Signal pathways in up-regulationof chemokines by tyrosine kinase MER/NYK in prostate cancer cells. Cancer Res64(20), 7311-7320.
49. Loges S, Schmidt T, Tjwa M, van Geyte K, Lievens D, Lutgens E, Vanhoutte D, Borgel D, Plaisance S, Hoylaerts M, et al. (2010). Malignant cells fuel tumorgrowth by educating infiltrating leukocytes to produce the mitogen Gas6. Blood 115, 2264-2273.
50. Ye X, Li Y, Stawicki S, Couto S, Eastham-Anderson J, Kallop D, Weimer R, Wu Y, and Pei L (2010). An anti-Axl monoclonal antibody attenuates xenografttumor growth and enhances the effect of multiple anticancer therapies. Oncogene 29, 5254-5264.